Brazilian clinical trials have unveiled that a COVID-19 vaccine developed by China's Sinovac has been found to be 50.4% effective, media reports said.
It shows the vaccine is significantly less effective than previous data suggested - barely over the 50% needed for regulatory approval, reports BBC.
The vaccine is one of the two which the Brazilian government has lined up.
Brazil is one of the worst-hit COVID-19 nations in the world.
Sinovac, a Beijing-based biopharmaceutical company, is behind CoronaVac, an inactivated vaccine. It works by using killed viral particles to expose the body's immune system to the virus without risking a serious disease response, reports BBC.
- Cholera’s continued spread in Haiti a ‘worrying trend’
- Countries held the line against malaria cases and deaths in 2021: WHO report
- China finally rolls back strict COVID rules amid weeks of protest
- Bangladesh plans to administer fourth COVID-19 booster shot from Dec 20
- Gaps in surveillance, testing, sequencing and vaccination are continuing to create perfect conditions for a new COVID-19 variant of concern to emerge: WHO